The Arcturus Therapeutics Holdings (NASDAQ:ARCT) Share Price Has Gained 114%, So Why Not Pay It Some Attention?HomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets open in 9 hrs 21 minsS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)The Arcturus Therapeutics Holdings (NASDAQ:ARCT) Share Price Has Gained 114%, So Why Not Pay It Some Attention?Simply Wall StSimply Wall St.January 10, 2020ReblogShareTweetShareView photosWhen you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right business to buy shares in, you can make more than you can lose. Take, for example Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT). Its share price is already up an impressive 114% in the last twelve months. Better yet, the share price has risen 7.7% in the last week. We'll need to follow Arcturus Therapeutics Holdings for a while to get a better sense of its share price trend, since it hasn't been listed for particularly long. See our latest analysis for Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.Over the last twelve months, Arcturus Therapeutics Holdings's revenue grew by 149%. That's stonking growth even when compared to other loss-making stocks. Meanwhile, the market has paid attention, sending the share price soaring 114% in response. It's great to see strong revenue growth, but the question is whether it can be sustained. Given the positive sentiment around the stock we're cautious, but there's no doubt its worth watching.The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).NasdaqGM:ARCT Income Statement, January 10th 2020MoreIt's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. So it makes a lot of sense to check out what analysts think Arcturus Therapeutics Holdings will earn in the future (free profit forecasts).A Different PerspectiveArcturus Therapeutics Holdings boasts a total shareholder return of 114% for the last year. We regret to report that the share price is down 0.3% over ninety days. Shorter term share price moves often don't signify much about the business itself. If you want to research this stock further, the data on insider buying is an obvious place to start. You can
click here to see who has been buying shares - and the price they paid.Arcturus Therapeutics Holdings is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextPublic Joint-stock Company TNS energo Mari El (MCX:MISB) Is Yielding 7.0% - But Is It A Buy?Simply Wall St.Some ISS (CPH:ISS) Shareholders Have Copped A Big 57% Share Price DropSimply Wall St.SalMar ASA Annual Results: Here's What Analysts Are Forecasting For Next YearSimply Wall St.bioMérieux S.A. Full-Year Results: Here's What Analysts Are Forecasting For Next YearSimply Wall St.Are Dividend Investors Getting More Than They Bargained For With Euroz Limited's (ASX:EZL) Dividend?Simply Wall St.Biocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoWhy We’re Not Keen On YHI International Limited’s (SGX:BPF) 3.8% Return On CapitalSimply Wall St.'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance Video